Matrix Biology 31 (2012) 187–196
Contents lists available at SciVerse ScienceDirect
Matrix Biology
journal homepage: www.elsevier.com/locate/matbio
Expression of collagen VI α5 and α6 chains in human muscle and in Duchenne
muscular dystrophy-related muscle fibrosis
Patrizia Sabatelli a,⁎, Francesca Gualandi b, Sudheer Kumar Gara c, Paolo Grumati d, Alessandra Zamparelli e,
Elena Martoni b, Camilla Pellegrini b, Luciano Merlini e, Alessandra Ferlini b, Paolo Bonaldo d,
Nadir Mario Maraldi e, Mats Paulsson c, f, g, Stefano Squarzoni a,⁎, 1, Raimund Wagener c, f, 1
a
CNR-National Research Council of Italy, Institute of Molecular Genetics-IOR, Bologna, Italy
Department of Experimental and Diagnostic Medicine, University of Ferrara, Italy
c
Center of Biochemistry, Medical Faculty, University of Cologne, D-50931, Germany
d
Department of Histology, Microbiology and Medical Biotechnologies, University of Padova, Italy
e
Laboratory of Musculoskeletal Cell Biology, Rizzoli Orthopaedic Institute, Bologna, Italy
f
Center for Molecular Medicine Cologne (CMMC), University of Cologne, D-50931, Germany
g
Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, D-50931, Germany
b
a r t i c l e
i n f o
Article history:
Received 8 August 2011
Received in revised form 13 December 2011
Accepted 19 December 2011
Keywords:
Collagen VI
Skeletal muscle
Myotendinous junctions
Fibrosis
Duchenne muscular dystrophy
a b s t r a c t
Collagen VI is a major extracellular matrix (ECM) protein with a critical role in maintaining skeletal muscle
functional integrity. Mutations in COL6A1, COL6A2 and COL6A3 genes cause Ullrich Congenital Muscular Dystrophy (UCMD), Bethlem Myopathy, and Myosclerosis. Moreover, Col6a1−/− mice and collagen VI deficient
zebrafish display a myopathic phenotype. Recently, two additional collagen VI chains were identified in
humans, the α5 and α6 chains, however their distribution patterns and functions in human skeletal muscle
have not been thoroughly investigated yet. By means of immunofluorescence analysis, the α6 chain was
detected in the endomysium and perimysium, while the α5 chain labeling was restricted to the myotendinous junctions. In normal muscle cultures, the α6 chain was present in traces in the ECM, while the α5
chain was not detected. In the absence of ascorbic acid, the α6 chain was mainly accumulated into the cytoplasm of a sub-set of desmin negative cells, likely of interstitial origin, which can be considered myofibroblasts as they expressed α-smooth muscle actin. TGF-β1 treatment, a pro-fibrotic factor which induces
trans-differentiation of fibroblasts into myofibroblasts, increased the α6 chain deposition in the extracellular
matrix after addition of ascorbic acid. In order to define the involvement of the α6 chain in muscle fibrosis we
studied biopsies of patients affected by Duchenne Muscular Dystrophy (DMD). We found that the α6 chain
was dramatically up-regulated in fibrotic areas where, in contrast, the α5 chain was undetectable. Our results
show a restricted and differential distribution of the novel α6 and α5 chains in skeletal muscle when compared to the widely distributed, homologous α3 chain, suggesting that these new chains may play specific
roles in specialized ECM structures. While the α5 chain may have a specialized function in tissue areas subjected to tensile stress, the α6 chain appears implicated in ECM remodeling during muscle fibrosis.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
Collagen VI is an extracellular matrix protein which forms a distinct
microfibrillar network in most connective tissues. It was long considered to consist of three genetically distinct α-chains (α1, α2 and α3),
secreted into the extracellular matrix where they form an extended
microfilamentous network (Chu et al., 1988; Knupp and Squire, 2001).
⁎ Corresponding authors at: CNR - National Research Council of Italy, Institute of Molecular Genetics-IOR, via di Barbiano 1/10, 40136 Bologna, Italy. Tel.: + 39 051
6366779; fax: + 39 051 583593.
E-mail addresses: [email protected] (P. Sabatelli), [email protected]
(S. Squarzoni).
1
These authors contributed equally.
0945-053X/$ – see front matter © 2012 Elsevier B.V. All rights reserved.
doi:10.1016/j.matbio.2011.12.003
The collagen VI α1, α2 and α3 chains form heterotrimeric monomers
that are assembled intracellularly to dimers and tetramers. After secretion, filaments are formed by end to end interactions of the preassembled tetramers, forming characteristic beaded filaments (Bruns,
1984) as visualized by the rotary shadowing electron microscopy technique (von der Mark et al., 1984; Sabatelli et al., 2001).
Collagen VI has a critical role in maintaining skeletal muscle functional
integrity; in fact, mutations in the COL6A1, COL6A2, and COL6A3 genes
cause a group of inherited muscular dystrophies, namely Ullrich congenital muscular dystrophy (UCMD) (Camacho Vanegas et al., 2001),
Bethlem myopathy (BM) (Jöbsis et al., 1996; Lampe and Bushby, 2005;
Gualandi et al., 2009), and Myosclerosis myopathy (Merlini et al., 2008).
Col6a1−/− mice show a complete absence of collagen VI chains
(Bonaldo et al., 1998; Gara et al., 2008) and display a myopathic
188
P. Sabatelli et al. / Matrix Biology 31 (2012) 187–196
phenotype associated with an impairment of the autophagy flux that determines the presence of dilated sarcoplasmic reticulum and abnormal
mitochondria: these present a latent dysfunction, that causes an increased
apoptosis of muscle fibers (Irwin et al., 2003; Grumati et al., 2010). Moreover, zebrafish models of the human collagen VI myopathies develop myopathy and display mitochondrial ultrastructural changes along with an
increased rate of spontaneous apoptosis (Telfer et al., 2010).
Collagen VI is also thought to be implicated in tissue remodelling
and wound healing, as variations in collagen VI expression have been
reported in many pathological conditions, like muscle and liver fibrosis
(Freise et al., 2009). Fibrosis is the most conspicuous pathological
change in dystrophic muscles; it is characterized by excessive accumulation of collagens and other ECM components, including collagen VI
(Zanotti et al., 2007) and is regulated by mechanisms involving cell–
cell and cell–matrix interactions, as well as by factors secreted into
the ECM. TGF-β1 is one of the most potent regulators of tissue wound
healing and fibrosis (Cutroneo, 2007). It is highly expressed in regenerating muscle after injury and in dystrophic muscles, including
Duchenne muscular dystrophy patients and mdx mice (Zhou et al.,
2006), carrying mutations in the dystrophin gene, and in MDC1A,
caused by mutations in LAMA2 gene (Zanotti and Mora, 2006).
Recently, three novel collagen VI chains, α4, α5 and α6 were identified (Fitzgerald et al., 2008; Gara et al., 2008). The new chains structurally resemble the collagen VI α3 chain, each of them consisting of
seven VWA domains followed by a collagenous domain, two or three
C-terminal VWA domains and chain specific domains. In mouse the
novel chains show a differential and restricted expression (Gara et
al., 2011). Since Col6a1 null mice do not deposit the new collagen
VI chains in the extracellular matrix, it was proposed that their assembly and secretion requires the presence of the α1 chain and that
the new chains may substitute for the α3 chain, probably forming
(α1 α2 and α4), (α1 α2 and α5) or (α1 α2 and α6) heterotrimers
(Gara et al., 2008, 2011). Due to a large scale pericentric inversion,
the human COL6A4 gene on chromosome 3 is broken into two pieces
and has become a non-processed pseudogene (Wagener et al., 2009).
In humans, COL6A5 mRNA expression is restricted to a few tissues, including lung, testis, and colon. In contrast, the COL6A6 mRNA was
found in a wide range of fetal and adult tissues, including lung, kidney, liver, spleen, thymus, heart, skeletal muscle, pancreas, testis
and uterus (Fitzgerald et al., 2008). Collagen VI α5 chain protein expression in humans was so far studied only in skin, where it was
found in a narrow zone just below the dermal epidermal basement
membrane and around blood vessels (Sabatelli et al., 2011). It was
earlier reported that the α5 chain is present in the epidermis
(Söderhäll et al., 2007), but this observation has been challenged
(Sabatelli et al., 2011). Collagen VI α6 protein expression in humans
was found in kidney, skeletal and cardiac muscle, lung, blood vessels,
pancreas, spleen and cartilage (Fitzgerald et al., 2008). However, collagen VI dependent disease is mainly manifested in muscle and the
precise localization of the novel chains has not been comprehensively
studied in this tissue yet. The discovery of two additional collagen VI
chains in humans adds a layer of complexity to collagen VI function in
the extracellular matrix (Fitzgerald et al., 2008; Gara et al., 2008).
To provide insight into the expression and function of the α5 and α6
collagen VI chains in human skeletal muscle, we studied these proteins
and the corresponding mRNAs in normal muscle tissue and cell cultures,
and in Duchenne Muscular Dystrophy (DMD) muscle with marked fibrosis, arisen independently from any mutation in the collagen VI genes.
normal subjects were stained with an antibody against the α6
chain. The α6 chain localized both in the perimysium and endomysium, with a less homogeneous pattern in the endomysium as compared to labeling obtained for the homologous α3 chain (Fig. 1a).
Double labeling with anti-α3 and α6 chains antibodies revealed a
partial co-localization (Fig. 1b), thus to better characterize the differential distribution of α3 and α6 chain, we performed double labeling
reactions with an antibody against the laminin γ1 chain, a marker of
the basement membrane of myofibers and blood vessels, and with an
antibody against collagen III, a component of the fibrillar matrix. The
α6 chain appeared mainly interstitial, in fact it was absent from the
basement membranes of both muscle and vessels, while it colocalized with collagen III (Fig. 1b). In contrast, the α3 chain was
detected at the basement membrane of myofibers and blood vessels,
as it co-localized with the laminin γ1 chain (Fig. 1b).
2. Results
We compared the expression and organization of the α5 and α6
chains with that of their homologue, the α3 chain, in a primary normal muscle cell culture under different culture conditions, i.e.
grown for 48 h (proliferating) or 7 days (long term), with and without 0.25 mM L-ascorbic acid, and after induction of myogenic differentiation. The α3 chain was detected in the extracellular matrix of
both proliferating and long-term samples, however the microfibrillar
2.1. Immunofluorescence analysis of the collagen VI α6 chain in normal
skeletal muscle
To assess the tissue distribution of the α6 chain in human skeletal
muscle, frozen sections of tibialis anterior and soleus, obtained from
2.2. The collagen VI α5 chain is selectively localized at the basement
membrane of myotendinous junctions
By immunofluorescence analysis, the α5 chain was not detected in
the endoysium and perimysium of tibialis anterior (Fig. 2), however,
when we analyzed a sample derived from the soleus muscle taken
at the insertion to the Achille's tendon, we found a selective expression of the α5 chain at the myotendinous junctions (MTJ) where it
co-localized with the laminin α2 chain, a marker for the basement
membrane of muscle fibers. The labeling pattern obtained with
pFAK antibodies, which are selectively expressed at the MTJ, mirrored
on the cytoplasmic side the α5 chain signal on the extracellular side
at the MTJ level (Fig. 2). The α5 chain was absent in the extrajunctional myofiber basement membrane and within the tendon
(Fig. 2). The α6 chain was also detected at the myotendinous junctions, though not as a specific localization but as a continuous labeling
of the endomysium. Similarly to the α5 chain, it was absent within
the tendon (data not shown).
2.3. COL6A1 homozygous null mutations affect the deposition of the collagen VI α6 chain in the extracellular matrix of skeletal muscle of an
UCMD patient
To assess if COL6A1 mutations affect the deposition of the novel α6
chain in the extracellular matrix of human muscle, in accordance with
the reported Col6a1 −/− mouse model (Gara et al., 2008), we studied
the muscle biopsy of an UCMD patient carrying a homozygous deletion in exon 22 that causes a frameshift, resulting in a premature
stop codon at residues 504–505 in the triple helical domain. At the
protein level, this mutation causes a complete absence of the α1
chain both in patient's cells and medium of cultured skin fibroblasts
(P3 in Giusti et al., 2005) and in muscle biopsy (Demir et al., 2004),
similar to the Col6a1 −/− mice phenotype (Bonaldo et al., 1998).
By immunofluorescence analysis we found that both the α3 and
the α6 chains were absent in the extracellular matrix (Supplementary
Fig. 1); we could not determine the effect of the COL6A1 mutation on
the α5 chain deposition since myotendinous junctions were not present
in the patient's biopsy, as detected by laminin γ1 chain (Supplementary
Fig. 1).
2.4. Collagen VI α5 and α6 chain expression in normal muscle cell
cultures
P. Sabatelli et al. / Matrix Biology 31 (2012) 187–196
189
Fig. 1. Immunofluorescence analysis of collagen VI α6 and α3 chains in transversal muscle sections of tibialis anterior from a normal subject.a: The α6 chain is expressed both in the
perimysium and endomysium, with a discontinuous pattern around the muscle fibers. α3 chain immunolabeling is diffuse and homogeneous both in the perimysium and endomysium. Bar, 100 μm. Nuclei were counterstained with DAPI (blue).b: α6 chain labeling appears discontinuous in the endomysium (arrows), and a partial co-localization with anti-α3
chain was shown with double labeling. The α3 chain antibody strongly stains basement membranes, as demonstrated by double-labeling for the laminin γ1 chain (yellow fluorescence in merge image); the α6 chain appears expressed in the interstitium between adjacent fibers and absent in basement membrane of both capillary vessels and myofibers. In
agreement with an interstitial localization, the α6 chain co-localizes with collagen type III. Bar, 20 μm. Nuclei were counterstained with DAPI (blue).
network appeared better organized and developed in long-term cultures (Fig. 3a). The α6 and α5 chains were not detectable in proliferating primary muscle cell cultures (not shown). In long-term cultures,
slight filamentous, α6-containing deposits were detected in the
extracellular matrix (Fig. 3b), while the α5 chain was completely absent (not shown). The α6 antibody co-localized with α3-positive filamentous structures, however, an α3-based independent network
could be also detected (Fig. 3b). COL6A5 transcripts were
Fig. 2. Immunofluorescence analysis of collagen VI α6 in human muscle.a: Collagen VI α5 chain localization in transversal sections of tibialis anterior (extra-junctional, left panel)
and of soleus at the insertion to the Achille's tendon (MTJ, middle and right panels). The α5 chain (green) is absent in the interstitium of tibialis anterior, while it is selectively
expressed at the myotendinous junction of soleus (arrows) where it co-localizes with the laminin α2 chain (red), a marker for basement membranes. Bar, 100 μm in left and middle
panels, and 20 μm in right upper and lower panels. Nuclei were counterstained with DAPI (blue).b: Double labeling with anti-α5 chain (green) and anti-pFAK (red) antibodies, of a
section of soleus at the insertion to the Achille's tendon, reveals that the α5 chain is expressed at the extracellular side of myotendinous junctions, where pFAK labeling is concentrated. The merged image shows a clear correspondence of the two labeling patterns. Bar, 20 μm. Nuclei were counterstained with DAPI (blue).
190
P. Sabatelli et al. / Matrix Biology 31 (2012) 187–196
Fig. 3. Immunofluorescence analysis of collagen VI α3 and α 6 chains in normal muscle cultures.a: The collagen VI α3 chain (red fluorescence) is detected in the extracellular matrix
of both proliferating and long-term (after ascorbic acid treatment for 7 days post-confluence) samples, however the arrangement of the collagen VI network appears better organized in long term cultures. Bar, 100 μm. Nuclei were counterstained with DAPI (blue).b: Collagen VI α6 chain (red fluorescence) deposits are detectable in the extracellular matrix
of muscle cultures after ascorbic acid treatment for 7 days post-confluence. α6-containing structures (arrows, left upper panel) show a filamentous arrangement, as detected at
higher magnification (right upper panel). Lower panels show double labeling with antibodies against the anti-α6 (red fluorescence) and α3 (green fluorescence) chains. Filamentous α6 chain-containing structures (red) co-localize with α3 chain-containing positive microfilaments, as revealed by the merged image (lower, right panel), however, an independent α3 chain-containing network (green fluorescence) can be also detected. Bar, 20 μm. Nuclei were counterstained with DAPI (blue).c: Real Time-PCR analysis of COL6A3 and
COL6A6 transcripts. Reported values are the mean of two different experiments utilizing ACTB and GAPDH as reference transcripts. The relative ratios ofCOL6A3/Actin-GAPDH and
COL6A6/Actin-GAPDH mRNAs in proliferating cells were normalized to 1. Both COL6A3 and COL6A6 transcript levels were increased in long-term cells (1.7:1 for COL6A6 and 2.9:1
for COL6A3).d: Immunofluorescence analysis of collagen VI α3 and α6 chains in long-term normal muscle cell cultures in the absence of ascorbic acid treatment. Samples were
double-labeled for desmin (upper panels, green fluorescence) and for α-smooth muscle actin (α-SMA; lower panels, green fluorescence). The collagen VI α3 chain (red fluorescence, left, upper panel) appears to be absent in desmin-positive cells and accumulates in desmin-negative cells, indicating that the fibroblasts are the main source of α3 chain.
Similarly, the α6 chain (red, right, upper panel) is absent in desmin-positive, but different from the α3 chain, it is detected intracellularly only in a subset of desmin-negative
cells. Cell producing collagen VI α6 chain (red) are positive for α-smooth muscle actin (green, right, lower panel), indicating that they could be myofibroblasts. Bar, 20 μm. Nuclei
were counterstained with DAPI (blue).
undetectable both in proliferating and in long-term cells. Both
COL6A3 and COL6A6 transcript levels were increased in long-term
cultures compared to proliferating cells (1.7:1 COL6A6 and 2.9:1
COL6A3) (Fig. 3c). Primary cultures derived from muscle biopsies
may contain both interstitial and myogenic cells. To assess which
cells produce the α6 chain, long-term muscle cultures were analyzed
in the absence of ascorbic acid, to induce intracellular accumulation of
under-hydroxylated collagen VI chains (Engvall et al., 1986). In agreement with a previous study which established that interstitial cells,
and not myogenic cells, produce collagen VI (Zou et al., 2008), we
found that the α3 chain was absent in myogenic (desmin-positive)
cells, while it was accumulated in most of desmin-negative cells.
The α6 chain was detected intracellularly only in a subset of
desmin-negative cells, and, similarly to the α3 chain, it was absent
in myogenic cells. Interestingly, most of the α6 chain-producing
cells showed a flattened shape and were positive for α-smooth muscle actin (α-SMA), indicating that they could be myofibroblasts, probably of interstitial origin (Fig. 3d).
Under differentiating conditions, the α3 chain was present both in
the extracellular matrix surrounding myotubes and inside the cytoplasm of desmin-negative cells. The presence of this protein inside
the cytoplasm can be ascribed to the absence of ascorbic acid in differentiating medium (Lattanzi et al., 2000). The α3 chain was not
detected inside the cytoplasm of myotubes, confirming that myogenic
cells do not produce collagen VI (Zou et al., 2008). The α6 chain was
faintly detected in the extracellular matrix as a poorly developed network. Some desmin-negative cells showed cytoplasmic labeling while
the protein was absent within myotubes (Supplementary Fig. 2). The
alpha5 chain was not detectable both in myotubes and desminnegative cells, similarly to proliferating and long-term cultures (not
shown). These data strongly indicate that regulation of both α5 and
α6 chains is not affected by myogenic differentiation.
2.5. Trans-differentiation of muscle fibroblasts into myofibroblasts induced by TGFβ1 strongly increases collagen VI α6 chain deposition in
the extracellular matrix of normal muscle cultures
TGFβ1 is a strong inducer of muscle fibroblasts activation, when
applied to primary muscle cell cultures, and of fibroblast differentiation into myofibroblasts, which acquire an α-SMA-positive phenotype. On the contrary, TGFβ1 inhibits myogenic differentiation. To
assess the effect of TGFβ1 on the expression of the novel collagen VI
chains, normal primary muscle cells were treated for 10 days. As
expected, we detected a strong increase in the number of α-SMA positive cells (Fig. 4a). In contrast, desmin expression was reduced, as
well as the number of spontaneously differentiated myotubes (not
shown). In these conditions, the amount of α6 chain was increased
and the secreted protein deposited in a wide filamentous network
in the extracellular matrix (Fig. 4a). The α6 chain mainly colocalized with the α3 chain, however, a distinct α3 chain containing
P. Sabatelli et al. / Matrix Biology 31 (2012) 187–196
191
Fig. 4. Immunofluorescence and Real Time-PCR analysis of α6 chain in normal muscle cultures after TGFβ1 treatment.a: After 10 days TGFβ1 treatment most of interstitial cells
express α-SMA (left upper panel, green fluorescence) indicating trans-differentiation into a myofibroblasts-like phenotype. In the absence of ascorbic acid (right upper panel)
most of α-SMA expressing cells accumulated the collagen VI α6 chain (red) intracellularly. After ascorbic acid treatment (left and right middle panels), the α6 chain (red) was
abundantly secreted and arranged in a wide filamentous network in the extracellular matrix. Left and right lower panels show double labeling with antibodies against the α6
and α3 chains on samples treated with TGFβ1 for 10 days in presence of ascorbic acid. The α6 chain (red fluorescence) mainly co-localizes with the α3 chain (green) labeling. However, a distinct α3−containing network can also be detected (green fluorescence). Bar, 20 μm . Nuclei were counterstained with DAPI (blue).b: Real Time-PCR analysis. Reported
values are the mean of two different experiments utilizing ACTB and GAPDH as reference transcripts The relative ratios of COL6A3/Actin-GAPDH and COL6A6/Actin-GAPDH mRNAs
in untreated cells were normalized to 1. COL6A3 and COL6A6 transcript levels are strongly reduced in cells after long-term (10 days) TGFβ1 treatment (0.48:1 for COL6A3 and
0.16:1 for COL6A6). Analysis of mRNA levels at different time points revealed constantly low transcriptional levels of COL6A6 mRNA starting from 24 hour of treatment. In contrast,
an initial slight up-regulation of COL6A3 mRNA at 24–48 hours, was followed by a gradual decrease after prolonged TGFβ1 treatment.
network could also be detected (Fig. 4a). Both COL6A3 and COL6A6
transcript levels were markedly reduced in cells after long-term
(10 days) TGFβ1 treatment (0.48:1 COL6A3 and 0.16:1 COL6A6). By
analyzing mRNA levels at different time points, we detected constantly low transcriptional levels of COL6A6 mRNA starting from 24 hour
of treatment. Differently, an initial up-regulation of COL6A3 mRNA
at 24–48 hours was followed by a gradual decrease at prolonged
TGFβ1 treatment (Fig. 4b). TGFβ1 treatment did not affect the expression and synthesis of the α5 chain, both at the RNA and protein levels
(not shown).
2.6. The collagen VI α6 chain, but not the α5 chain, is up-regulated in
dystrophic muscles
As myofibroblasts play a major role upon fibrosis, we studied the
expression of the α6 chain in muscle biopsies of five patients affected
by Duchenne Muscular Dystrophy (DMD), a muscular dystrophy
characterized by a marked fibrosis which is definitely independent
from any mutation in collagen VI genes. Because of scarce availability
of tissue, only the DMD815 biopsy was studied by means of immunofluorescence, Western blotting and mRNA analysis. The other DMD
patients were studied either by immunofluorescence plus mRNA or
by immunofluorescence plus Western blotting analysis.
By immunofluorescence analysis, the α6 chain antibody showed
an increased amount of protein in the extracellular matrix of all
DMD patients (Fig. 5a and Supplementary Fig. 3a). The localization
of the α6 chain was interstitial, in fact no labeling was detected at
the basement membrane of myofibers and blood vessels, as indicated
by double labeling with anti-laminin γ1 antibody (Fig. 5a). By double
staining, the α6 chain labeling correlated with collagen III positive
areas, used as a marker of fibrosis. Semiquantitative analysis revealed
a strong correlation between the increase of α6 chain and collagen III
protein amount (supplementary Fig. 3b,c). Also the α3 chain was increased in all DMD patients (Fig. 5b) and matched the degree of fibrosis. Double labeling with antibodies against the α3 and α6 chains
showed a partial co-localization, and confirmed the absence of the
α6 chain from the basement membranes of vessels and myofibers.
At high magnification, undulated/wavy bundles of fibrils of different
size containing both the α6 and α3 chains were detected in fibrotic
areas (Fig. 5c), suggesting that the α6 and α3 chains may coassemble and cooperate in remodeling the extracellular matrix
upon fibrosis. Western blot analysis confirmed the increase of α3
and α6 chains in the three DMD patients examined (DMD815,
DMD1112, DMD1179). The increased protein levels of α3 and α6
chains matched with a general increase of collagen VI as shown by
α1 immuno-blotting (Fig. 6a). The protein increase matched a relevant increase of COL6A6 transcript level, with a fold change that ranged from 10 to 14 in the three analyzed DMD muscles (DMD815,
DMD1 and DMD23, Fig. 6b). Nevertheless, at the transcriptional
level, the increase in COL6A3 mRNA in fibrotic DMD muscles (2–4
fold changes) was significantly lower than the increase in COL6A6
mRNA. In contrast, the α5 chain and the corresponding transcript
were not detected (not shown).
3. Discussion
The discovery of two additional collagen VI chains in humans (α5
and α6), which may substitute for the α3 chain, suggests the existence of additional assembly forms of collagen VI (Fitzgerald et al.,
2008; Gara et al., 2008, 2011). So far, the localization and the expression pattern of the novel chains in human skeletal muscle, the tissue
most affected by collagen VI deficiency, was mostly unknown, with
the exception of their reported presence in commercially available
samples such as fetal human skeletal muscle extract and non-
192
P. Sabatelli et al. / Matrix Biology 31 (2012) 187–196
Fig. 5. Immunofluorescence analysis of α6 chain in DMD patients muscle biopsies.a:
Immunofluorescence analysis of the collagen VI α6 chain (red) and the laminin γ1
chain (green) in muscle sections of three patients affected by Duchenne muscular dystrophy (DMD815, DMD1, DMD23). α6 chain labeling appears increased in the endomysium and perimysium, with its increase correlating with the degree of fibrosis. The α6
chain localization is strictly interstitial, as demonstrated by absence of co-localization
with the laminin γ1 chain (right panels, green fluorescence),a marker for basal lamina.
Bar, 100 μm.b: Immunofluorescence analysis of the collagen VI α3 chain in DMD815
muscle sections revealed a marked increase in fibrotic ares (red fluorescence, left
panel). Double labeling with antibodies against –the laminin γ1 chain (green) reveals
the presence of α3 chain at the basal lamina of muscle fibers (yellow fluorescence in
merge image, right panel).c: High magnification of a muscle section from patient
DMD815 double labeled with antibodies against collagen VI α6 (red fluorescence)
and -α3 (green fluorescence) chains showing the presence of undulated/wavy bundles
of fibrils of different size containing both the α6 and α3 chains. In the basement membrane of a muscle fiber, only the α3 chain is found (arrows). Bar, 20 μm. Nuclei were
counterstained with DAPI (blue).
specified skeletal muscle tissue derived from a normal adult human
tissue panel (Fitzgerald et al., 2008).
Our study aims to define more precisely the expression and distribution of collagen VI α5 and α6 chains in mature human skeletal
muscle. In fact we show that in human skeletal muscle, the α5 and
α6 chains differ from the homologous α3 chain in a number of aspects, e.g. localization pattern, cellular origin and involvement in
ECM remodelling upon muscle fibrosis. To distinguish between the
different assembly forms (Gara et al., 2008), we used antibodies specific for the individual α3, α5 and α6 chains (Sabatelli et al., 2011).
In normal skeletal muscle sections, the α5 chain was selectively
detected at the basement membrane of myotendinous junctions.
Our previous studies showed that the α5 chain localizes at junctional
sites also in human skin, in particular at the dermal-epidermal junction (Sabatelli et al., 2011). These data indicate that α5 chaincontaining collagen VI microfibrils may have a specific function in
specialized tissue areas subjected to tensile stress. Myotendinous
junctions are crucial elements in the transmission of mechanical
force from the muscle via tendons to the skeletal elements. Several
molecules have been identified at this site and mutations in their
genes lead to pathologic changes of myotendinous junctions: α7β1
integrin, laminin 2, and the dystrophin glycoprotein complex are pivotal at this site (Mayer et al., 1997; Pegoraro et al., 2002; Vainzof and
Zatz, 2003). Tenascin, an oligomeric extracellular matrix protein, was
one of the first myotendinous junction markers (Chiquet and
Fambrough, 1984). Notably, mutations in tenascin XB gene cause
Ehlers–Danlos syndrome (Zweers et al., 2003), with muscle weakness
and contractures and secondary deficiency of collagen VI, overlapping
with the collagen VI myopathies phenotype (Voermans et al., 2007),
and pointing to a possible functional interaction between these myotendinous junction components. Therefore α5 gene mutation screening might result appealing in those cases of Ehlers–Danlos disease
which are negative for known mutations.
The α6 chain was less abundant than the homologous α3 chain.
Its localization was mainly interstitial where it partially co-localized
with the α3 chain. The most relevant difference between the α6
and α3 chain localization was the absence of the α6 chain in the basement membrane of both muscle fibers and vessels, where in contrast
the α3 chain was specifically detected. Considering that also the α5
chain is absent at the extrajunctional basement membrane, it is possible that the α3-containing microfibrils represent the specific basement membrane collagen VI form. This hypothesis is supported by
recent immunoelectron microscopy studies performed with antibodies specific for the collagen VI α1 α2 α3(VI) heterotrimer,
which confirmed basement membrane localization of this collagen
VI form in skeletal muscle fibers (Gara et al., 2011) and endothelial
cells (Groulx et al., 2011). It is interesting to note that absence/reduction of collagen VI at the basement membrane of muscle are features
of UCMD/BM muscle biopsies obtained from patients carrying mutations in COL6A1, COL6A2 and COL6A3 genes (Ishikawa et al., 2004;
Kawahara et al., 2007; Merlini et al., 2008; Gualandi et al., 2009).
Basement membrane abnormalities have also been detected in muscle fibers of Ullrich congenital muscular dystrophy patients
(Niiyama et al., 2002; Squarzoni et al., 2006) and in blood vessels of
Myosclerosis myopathy patients (Merlini et al., 2008). These data
point to a pivotal role of α1 α2 α3 collagen VI form in maintaining
basement membrane functional integrity.
As it has been shown for cartilage and skin, the expression of the
novel chains in muscle also differs between man and mouse
(Fitzgerald et al., 2008; Gara et al., 2011; Sabatelli et al., 2011).
Whereas the α5 chain in man is selectively expressed at the myotendinous junction, in mouse the α5 chain is strongly expressed in perimysium and sparsely in epimysium and, in addition, in perineurium
of intramuscular peripheral nerves and at the basement membrane
of neuromuscular junctions (Gara et al., 2011). The differences in tissue distribution between man and mouse could be the result of α4
chain gene loss in humans, which leads to a functional reorientation of the remaining chains. In contrast to this, the expression
of the α6 chain is similar in human and mouse skeletal muscle. In
agreement with reported studies on the Col6a1 null mice model, the
α6 collagen VI chain was not expressed in the skeletal muscle of a
UCMD patient carrying an α1 null mutation. This result indicates
that in humans, similarly to mice, the α6 chain co-assemble with
the α1 chain (Gara et al., 2008).
To define the organization of novel collagen VI chains in the extracellular matrix we analyzed normal skeletal muscle cultures. Filamentous α6 chain deposits were detectable in the extracellular matrix
only in long term cultures where α6 chain-containing networks
were less abundant and organized than those containing the α3
P. Sabatelli et al. / Matrix Biology 31 (2012) 187–196
193
Fig. 6. Western blot and RT-PCR analysis of collagen VI chains in muscle biopsies of DMD patients.a: Western blot analysis of skeletal muscles extracts from a healthy control
(CTRL1,2) and from DMD815, DMD1112 and DMD1179 patients. Proteins were separated by SDS-PAGE under reducing conditions and detected with polyclonal antibodies specific
for the collagen VI α6 and α3 and α1 chains; actin was used as loading control.b: Real Time-PCR analysis of COL6A6 transcripts in DMD skeletal muscle biopsies. Reported values are
the mean of two different experiments utilizing ACTB and GAPDH as reference transcripts. The relative ratios of COL6A3/Actin-GAPDH and COL6A6/Actin-GAPDH mRNAs in control
muscle were normalized to 1. The increased amount of collagen VI α3 and α6 chains in DMD muscles matched with an increase of the corresponding mRNAs. The COL6A6 transcript
level showed a fold change that ranged from 10 to 14 in the three analyzed samples whereas the variation in the COL6A3 mRNA level was lower (2–4 fold change).
chain. A co-localization was observed, indicating that secreted α3 and
α6 chains may co-assemble and form a common network, while the
presence of a distinct α3-based network confirmed the immunohistochemical pattern observed in tissue sections.
The α5 chain was absent both at the protein and the mRNA level
in proliferating and long term cultures. This is possibly due to the origin of the culture, in fact the muscle fragment we used to establish
primary cultures did not include myotendinous junctions. On the
other hand, the absence of the α5 chain demonstrates that it is dispensable for cell-substrate adhesion under normal conditions and
might underscore a specificity of this chain for junctional structures.
We determined which cells synthesize α6 chain in a primary muscle culture, as this contains both myogenic (desmin-positive) and interstitial (desmin-negative) cells. Collagen VI-producing cells could
be identified by omitting ascorbic acid treatment (Prockop et al.,
1976; Engvall et al., 1986), as they in this conditions display an intracellular staining with antibodies against collagen VI. The α3 chain
was accumulated in desmin-negative cells only, confirming that it is
produced by interstitial but not by myogenic cells (Zou et al., 2008).
The α6 chain was also absent in desmin-positive cells, but, in contrast
to the α3 chain, the α6 chain was detected intracellularly only in a
subset of desmin-negative cells which resulted to be α-SMA positive,
likely myofibroblasts of interstitial origin.
As TGFβ1 treatment induces transdifferentiation of interstitial
muscle fibroblasts to a myofibroblast phenotype (Zanotti et al.,
2010), we evaluated its effect on α5 and α6 chain expression and deposition in extracellular matrix. A striking increase in the number of
α-SMA-positive cells was observed after 10 days treatment, indicating that the treatment induced transdifferentiation. In addition,
TGFβ1 treatment induced a marked increase of the α6 chaincontaining filamentous network in the ECM, which only partially
overlapped with labeling for α3 chains. In contrast, α5 chain expression remained undetectable, even after TGFβ1 treatment. As
expected, and in contrast with the α6 chain increase, desmin expression was reduced, as well as the number of spontaneously differentiated myotubes.
Time course Real Time-PCR experiments showed down-regulation
of COL6A6 mRNA levels, starting from 24 h of TGFβ1 treatment, indicating that in the cell culture model, despite a very early induction occurred, the increased protein amounts cannot be ascribed to a direct
effect of TGFβ1 on COL6A6 transcription.
Previous studies reported that in vitro treatment with TGF-β1 induces the expression of several collagen VI interacting proteins, as
collagens I and IV (Evans et al., 2003), biglycan (Todorova et al.,
2011), as well as fibronectin and integrins (Reinboth et al., 2006;
Honda et al., 2010). It is possible that TGF-β1 treatment improves
the efficiency of the extracellular binding/assembly of the α6 chain
by induction of collagen VI related-proteins, resulting in an increased
deposition in the extracellular matrix.
Our results indicate that myofibroblasts are the main α6 chain
producing cells and that TGF-β1 treatment enhances α6 chain secretion, pointing to a possible involvement of the α6 chain in fibrosis
(Wipff and Hinz, 2008). Fibrosis is a conspicuous pathological change
in dystrophic muscles. It is characterized by excessive accumulation
of collagens and other ECM components including collagen VI. For
this reason we evaluated the expression of α5 and α6 chains in muscle biopsies of three DMD patients with different degrees of fibrosis.
We found that collagen VI was generally increased in fibrotic muscle
and, in particular, the α6 chain was strongly up-regulated in DMD
muscle at protein level, as shown by Western blot, real time PCR
and immuno-histochemical analysis. The increase of the α6 chain
was particularly evident in fibrotic areas and maintained an interstitial localization at the endomysium, since no colocalization with basement membrane markers was detected.
On the basis of their high homology with the α3 chain, the collagen VI α5 and α6 chains are likely to interact with α1 and α2 chains,
in agreement with previous studies on Col6a1 knockout mice (Gara
et al., 2008, 2011) and on human skin (Sabatelli et al., 2011). This
may give rise to homologous heterotrimers, which appear to function
differently, most probably with regard to tissue adhesion. Specifically,
in human skeletal muscle we hypothesize that the α3-containing collagen VI is involved in basement membranes adhesion to the interstitial extracellular matrix; the α5-containing collagen VI is involved in
junctional adhesion at myotendinous junctions and dermalepidermal junctions, and the α6-containing collagen VI has a role in
adhesion to endomysium and in the development of fibrosis, in association with fibrillar collagen. Future studies will concern the role of
the novel collagen VI chains in human disease. Moreover, since our
data suggest specific roles in specialized ECM structures for α5 and
α6 chains, being the α5 related to tensile stress and the α6 implicated in ECM fibrotic remodelling, they might respectively represent
new biomarkers for monitoring these stressing events.
194
P. Sabatelli et al. / Matrix Biology 31 (2012) 187–196
4. Experimental procedures
4.1. Preparation of antibodies against the new collagen VI chains
The purified recombinant collagen VI fragments were used to immunize rabbits and guinea pigs. The antisera obtained were purified
by affinity chromatography on a column with antigen coupled to
CNBr-activated Sepharose (GE Healthcare). The specific antibodies
were eluted with 0.1 M glycine, pH 2.5, and the eluate was neutralized with 1 M Tris–HCl, pH 8.8 (Sabatelli et al., 2011).
4.2. Patients
All subjects studied granted informed consent. Skeletal muscle biopsies of one soleus at the insertion with Achille's tendon and two
tibialis anterior from healthy subjects, tibialis anterior from five
DMD patients and gastrocnemius from one UCMD patient were frozen in isopentane pre-chilled in liquid nitrogen and stored in liquid
nitrogen. All patients (Table 1) were previously diagnosed by genetic
and immunohistochemical analysis.
4.3. Immunofluorescence analysis
Frozen sections (7 μm-thick) from muscles of healthy donors and
of five DMD (DMD1, DMD815, DMD23, DMD1112 and DMD1179)
and one UCMD patients (see Table 1) were incubated with the affinity
purified rabbit polyclonal antibody against the collagen VI α5 chain
(diluted in PBS 1/40). For the immunofluorescence analysis of the collagen α6 chain, frozen sections from healthy donors and patients
were fixed with 2% paraformaldehyde in phosphate buffered saline
(PBS), washed in PBS and permeabilized with 0.15% Triton X100, saturated with 5% normal goat serum (Sigma) and incubated with the
rabbit or guinea pig antibody against the α6 chain diluted 1/40. All
sections were developed with anti-rabbit or anti-guinea pig TRITC
or FITC-conjugated IgG (DAKO) and double labeled with mouse
monoclonal antibodies against the laminin γ1, laminin α2 chain, collagen type III (Chemicon), or with anti-pp125 FAK antibody (Santa
Cruz) and revealed with anti-mouse or anti-rabbit FITC or TRITCconjugated secondary antibodies (DAKO). An antibody against the
collagen VI α1α2α3 chains (Fitzgerald) was used on sections of the
UCMD patient to assess the expression of collagen VI. Samples were
mounted with an anti-fading reagent (Molecular Probes) and observed with a Nikon epifluorescence microscope. Nuclei were counterstained with DAPI.
The proliferation of connective tissue in DMD muscle biopsies was
evaluated by immunofluorescence analysis of collagen type III
(Hantaï et al., 1985) and compared with the normal muscle biopsy.
Double labeling with anti-α6 chain antibody was performed in
order to evaluate whether collagen III-positive areas correlated with
the alpha6 chain labeling. Five different fields for each biopsy were
taken with a fixed exposure time by the NIS-Elements AR (Nikon) imaging program using the multi-channel acquisition function. All images, which included both signals for the collagen VI α6 chain and
for collagen III, were captured using an high-resolution CCD camera
(Nikon). Semi-quantitative analysis was performed by a software developed in cooperation with Nikon Italy (NIS-Elements 3.0 AR imaging program, Nikon). The fluorescent areas were evaluated by the
area fraction function, and the mean values were calculated. For
graphic representation, area fraction mean values were expressed as
percentage. Data were analyzed using the Mann–Whitney test and
the significance was calculated versus normal muscle.
4.4. Muscle cultures
Primary muscle cells derived from tibialis anterior of a normal
subject were established as described (Cenni et al., 2005) and
maintained in D-MEM plus 20% fetal calf serum (Rando and Blau,
1994). For immunofluorescence analysis of the collagen VI α5 and
α6 chains muscle cells were grown onto coverslips for 48 hrs or
7 days, with and without 0.25 mM L-ascorbic acid. When needed,
cells were treated with 10 ng/ml TGF-β1 (Sigma). Differentiation
to myotubes was induced by incubating subconfluent cells for
7 days with D − MEM plus 10% fetal calf serum (Lattanzi et al.,
2000). Samples were fixed with cold methanol, washed with PBS
and incubated with rabbit or guinea pig antibodies against the
α5, α6 or α3 chains. Double labeling was performed with mouse
monoclonal anti-desmin (Novocastra) or anti-alpha-SMA (SIGMA)
antibodies. Nuclei were counterstained with DAPI
4.5. Quantification of COL6A5 and COL6A6 transcripts by real-time PCR
Total RNA was isolated from muscle sections of normal tibialis or
tibialis from patients DMD815, DMD1 and DMD23 or from cell cultures by using RNeasy Kit (QIAGEN, Chatsworth, CA) and reverse
transcribed by using High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). In order to quantify the steady state level of
COL6A5 and COL6A6 transcripts, commercially available TaqMan expression assays (Applied Biosystems) were used for target genes
(COL6A3: Hs00915102_m1 Ex 23–24; COL6A5 (COL29A1):
Hs00542046_m1 exons 35–36; COL6A6: Hs01029204_m1 exons
12–13) and for β actin and GAPDH as housekeeping reference genes
(ACTB Endogenous Control- GAPDH endogenous control). Real-time
PCR was performed in triplicate on the Applied Biosystems Prism
7900HT system, using 10 ng of cDNA and default parameters. Evaluation of COL6A3 and COL6A6 transcripts levels was performed by the
comparative CT method (ΔΔCT Method; Applied Biosystems User
Bullettin #2). cDNAs from control muscle sections or untreated cells
were utilized as calibrators.
4.6. Western blot analysis
Frozen sections (20 μm) were prepared from skeletal muscles biopsies of two healthy donors and patients DMD815, DMD1112 and
DMD1179. The sections were extracted by incubation for 10 min at
70 °C in a lysis solution containing 50 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 10 mM MgCl2, 2% SDS, 1% Triton X-100, 0.5 mM dithiothreitol,
Table 1
Table of muscle biopsies.
Patient
Age of biopsy (years_months)
Sex
Disease status
Muscle type
Mutation
DMD1
DMD815
DMD23
DMD1112
DMD1179
UCMD
CTRL2
CTRL1120
CTRL8
4.7
10.2
9.1
0.9
11
1.5
10
9
35
Male
Male
Male
Male
Male
Male
Male
Female
Male
Slow in running
Unable to climb stairs
Difficulty with stairs
Delayed motor milestones
Unable to climb stairs
Sitter, diffuse muscle wasting and weakness
Healthy donor
Healthy donor
Healthy donor
Tibialis
Tibialis
Tibialis
Tibialis
Tibialis
Gastrocnemius
Tibialis
Tibialis
Tibialis
del 51
splicing in 25c_3641-1G>A
del45-52
c_5551C>T
del 1M-2
COL6A1 IG del 1456nt (Giusti et al., 2005)
P. Sabatelli et al. / Matrix Biology 31 (2012) 187–196
1 mM ethylenediaminetetraacetic acid, 10% glycerol and protease inhibitors. For each sample, the total protein content was determinate
using “BCA Protein Assay Kit” (Pierce). Samples were reduced with
5% β-mercaptoethanol and separated by SDS-PAGE on 3-8% (w/v)
gradient polyacrylamide gels. Collagen VI α3 and α6 chains were
detected using the affinity-purified antibodies developed in rabbit
(Sabatelli et al., 2011). Collagen VI α1 chain was detected using a specific collagen VI α1 antibody (H-200, Santa Cruz Biotechnologies). As
a loading control, actin was used (Sigma). Secondary antibodies conjugated with horseradish peroxidase were employed (GE Healthcare)
and bands detected by chemiluminescence (SuperSignal West Pico,
Pierce).
Supplementary materials related to this article can be found online at doi:10.1016/j.matbio.2011.12.003.
Acknowledgments
This work has been funded by the BIO-NMD Grant (EC, 7th FP,
proposal #241665; “http://www.bio-nmd.eu” to AF as coordinator)
and Italian Research Ministry “Prin 2008” grant no. 2008PB5S89 to
PB, PS, SS, AF, by Fondazione CaRisBo and by the Deutsche
Forschungsgemeinschaft (WA1338/2-6 and SFB 829) to RW and MP.
SKG is a member of the International Graduate School in Genetics
and Functional Genomics at the University of Cologne. The authors
wish to thank Dr Rosa Curci for assistance in human muscle cultures
establishment.
References
Bonaldo, P., Braghetta, P., Zanetti, M., Piccolo, S., Volpin, D., Bressan, G.M., 1998.
Collagen VI deficiency induces early onset myopathy in the mouse: an animal
model for Bethlem myopathy. Hum. Mol. Genet. 7, 2135–2140.
Bruns, R.R., 1984. Beaded filaments and long-spacing fibrils: relation to type VI collagen. J. Ultrastruct. Res. 89, 136–145.
Camacho Vanegas, O., Bertini, E., Zhang, R.Z., Petrini, S., Minosse, C., Sabatelli, P., Giusti,
B., Chu, M.L., Pepe, G., 2001. Ullrich scleroatonic muscular dystrophy is caused by
recessive mutations in collagen type VI. Proc. Natl. Acad. Sci. U. S. A. 98, 7516–7521.
Cenni, V., Sabatelli, P., Mattioli, E., Marmiroli, S., Capanni, C., Ognibene, A., Squarzoni, S.,
Maraldi, N.M., Bonne, G., Columbaro, M., Merlini, L., Lattanzi, G., 2005. Lamin A Nterminal phosphorylation is associated with myoblast activation: impairment in
Emery–Dreifuss muscular dystrophy. J. Med. Genet. 42, 214–220.
Chiquet, M., Fambrough, D.M., 1984. Chick myotendinous antigen. I. A monoclonal antibody as a marker for tendon and muscle morphogenesis. J. Cell Biol. 98,
1926–1936.
Chu, M.L., Conway, D., Pan, T.C., Baldwin, C., Mann, K., Deutzmann, R., Timpl, R., 1988.
Amino acid sequence of the triple-helical domain of human collagen type VI. J.
Biol. Chem. 263, 18601–18606.
Cutroneo, K.R., 2007. TGF-beta-induced fibrosis and SMAD signaling: oligo decoys as
natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair
Regen. 15, S54–S60.
Demir, E., Ferreiro, A., Sabatelli, P., Allamand, V., Makri, S., Echenne, B., Maraldi, N.M.,
Merlini, L., Topaloglu, H., Guicheney, P., 2004. Collagen VI status and clinical severity in Ullrich congenital muscular dystrophy: phenotype analysis of 11 families
linked to the COL6 loci. Neuropediatrics 35, 103–112.
Engvall, E., Hessle, H., Klier, G., 1986. Molecular assembly, secretion, and matrix deposition of type VI collagen. J. Cell Biol. 102, 703–710.
Evans, R.A., Tian, Y.C., Steadman, R., Phillips, A.O., 2003. TGF-beta1-mediated fibroblastmyofibroblast terminal differentiation-the role of Smad proteins. Exp. Cell. Res.
282, 90–100.
Fitzgerald, J., Rich, C., Zhou, F.H., Hansen, U., 2008. Three novel collagen VI chains, alpha
4 VI, alpha 5 VI and alpha 6 VI. J. Biol. Chem. 283, 20170–20180.
Freise, C., Erben, U., Muche, M., Farndale, R., Zeitz, M., Somasundaram, R., Ruehl, M.,
2009. The alpha 2 chain of collagen type VI sequesters latent proforms of matrixmetalloproteinases and modulates their activation and activity. Matrix Biol. 28,
480–489.
Gara, S.K., Grumati, P., Urciuolo, A., Bonaldo, P., Kobbe, B., Koch, M., Paulsson, M.,
Wagener, R., 2008. Three novel collagen VI chains with high homology to the
{alpha}3 chain. J. Biol. Chem. 283, 10658–10670.
Gara, S.K., Grumati, P., Squarzoni, S., Sabatelli, P., Urciuolo, A., Bonaldo, P., Paulsson, M.,
Wagener, R., 2011. Differential and restricted expression of novel collagen VI
chains in mouse. Matrix Biol. 30, 248–257.
Giusti, B., Lucarini, L., Pietroni, V., Lucioli, S., Bandinelli, B., Sabatelli, P., Squarzoni, S.,
Petrini, S., Gartioux, C., Talim, B., Roelens, F., Merlini, L., Topaloglu, H., Bertini, E.,
Guicheney, P., Pepe, G., 2005. Dominant and recessive COL6A1 mutations in Ullrich
scleroatonic muscular dystrophy. Ann. Neurol. 58, 400–410.
195
Groulx, J.F., Gagné, D., Benoit, Y.D., Martel, D., Basora, N., Beaulieu, J.F., 2011. Collagen VI
is a basement membrane component that regulates epithelial cell-fibronectin interactions. Matrix Biol. 30, 195–206.
Grumati, P., Coletto, L., Sandri, M., Bonaldo, P., 2010. Autophagy is defective in collagen
VI muscular dystrophies, and its reactivation rescues myofiber degeneration. Nat.
Med. 16, 1313–1320.
Gualandi, F., Urciuolo, A., Martoni, E., Sabatelli, P., Squarzoni, S., Bovolenta, M., Messina,
S., Mercuri, E., Franchella, A., Ferlini, A., Bonaldo, P., Merlini, L., 2009. Autosomal recessive Bethlem myopathy. Neurology 73, 1883–1891.
Hantaï, D., Labat-Robert, J., Grimaud, J.A., Fardeau, M., 1985. Fibronectin, laminin, type I,
III and IV collagens in Duchenne's muscular dystrophy, congenital muscular dystrophies and congenital myopathies: an immunocytochemical study. Connect. Tissue Res. 13, 273–281.
Honda, E., Yoshida, K., Munakata, H., 2010. Transforming growth factor-beta upregulates the expression of integrin and related proteins in MRC-5 human myofibroblasts. Tohoku J. Exp. Med. 220, 319–327.
Irwin, W., Bergamin, N., Sabatelli, P., Reggiani, C., Megighian, A., Merlini, L., Braghetta,
P., Columbaro, M., Volpin, D., Bressan, G.M., Bernardi, P., Bonaldo, P., 2003. Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat. Genet. 35, 367–371.
Ishikawa, H., Sugie, K., Murayama, K., Awaya, A., Suzuki, Y., Noguchi, S., Hayashi, Y.K.,
Nonaka, I., Nishino, I., 2004. Ullrich disease due to deficiency of collagen VI in the
sarcolemma. Neurology 62, 620–623.
Jöbsis, G.J., Keizers, H., Vreijling, J.P., de Visser, M., Speer, M.C., Wolterman, R.A., Baas, F.,
Bolhuis, P.A., 1996. Type VI collagen mutations in Bethlem myopathy, an autosomal dominant myopathy with contractures. Nat. Genet. 14, 113–115.
Kawahara, G., Okada, M., Morone, N., Ibarra, C.A., Nonaka, I., Noguchi, S., Hayashi, Y.K.,
Nishino, I., 2007. Reduced cell anchorage may cause sarcolemma-specific collagen
VI deficiency in Ullrich disease. Neurology 69, 1043–1049.
Knupp, C., Squire, J.M., 2001. A new twist in the collagen story—the type VI segmented
supercoil. EMBO J. 20, 372–376.
Lampe, A.K., Bushby, K.M., 2005. Collagen VI related muscle disorders. J. Med. Genet.
42, 673–685.
Lattanzi, G., Muntoni, F., Sabatelli, P., Squarzoni, S., Maraldi, N.M., Cenni, V., Villanova,
M., Columbaro, M., Merlini, L., Marmiroli, S., 2000. Unusual laminin alpha2 processing in myoblasts from a patient with a novel variant of congenital muscular dystrophy. Biochem. Biophys. Res. Commun. 277, 639–642.
Mayer, U., Saher, G., Fässler, R., Bornemann, A., Echtermeyer, F., von der Mark, H.,
Miosge, N., Pöschl, E., von der Mark, K., 1997. Absence of integrin alpha 7 causes
a novel form of muscular dystrophy. Nat. Genet. 17, 318–323.
Merlini, L., Martoni, E., Sabatelli, P., Squarzoni, S., Bovolenta, M., Messina, S., Mercuri, E.,
Franchella, A., Ferlini, A., Bonaldo, P., 2008. Autosomal recessive myosclerosis myopathy is a collagen VI disorder. Neurology 71, 1245–1253.
Niiyama, T., Higuchi, I., Suehara, M., Hashiguchi, T., Shiraishi, T., Nakagawa, M., Arimura,
K., Maruyama, I., Osame, M., 2002. Electron microscopic abnormalities of skeletal
muscle in patients with collagen VI deficiency in Ullrich's disease. Acta Neuropathol. 104, 67–71.
Pegoraro, E., Cepollaro, F., Prandini, P., Marin, A., Fanin, M., Trevisan, C.P., ElMesslemani, A.H., Tarone, G., Engvall, E., Hoffman, E.P., Angelini, C., 2002. Integrin
alpha 7 beta 1 in muscular dystrophy/myopathy of unknown etiology. Am. J.
Pathol. 160, 2135–2143.
Prockop, D.J., Berg, R.A., Kivirikko, K.I., Uitto, J., 1976. In: Ramachandran, G.N., Reddi,
A.H. (Eds.), Biochemistry of Collagen. Plenum Press, New York, pp. 163–273.
Rando, T.A., Blau, H.M., 1994. Primary mouse myoblast purification, characterization,
and transplantation for cell-mediated gene therapy. J. Cell Biol. 125, 1275–1287.
Reinboth, B., Thomas, J., Hanssen, E., Gibson, M.A., 2006. Beta ig-h3 interacts directly
with biglycan and decorin, promotes collagen VI aggregation, and participates in
ternary complexing with these macromolecules. J. Biol. Chem. 281, 7816–7824.
Sabatelli, P., Bonaldo, P., Lattanzi, G., Braghetta, P., Bergamin, N., Capanni, C., Mattioli, E.,
Columbaro, M., Ognibene, A., Pepe, G., Bertini, E., Merlini, L., Maraldi, N.M., Squarzoni, S., 2001. Collagen VI deficiency affects the organization of fibronectin in the
extracellular matrix of cultured fibroblasts. Matrix Biol. 20, 475–486.
Sabatelli, P., Gara, S.K., Grumati, P., Urciuolo, A., Gualandi, F., Curci, R., Squarzoni, S.,
Zamparelli, A., Martoni, E., Merlini, L., Paulsson, M., Bonaldo, P., Wagener, R.,
2011. Expression of the collagen VI α5 and α6 chains in normal human skin and
in skin of patients with collagen VI-related myopathies. J. Invest. Dermatol. 131,
99–107.
Söderhäll, C., Marenholz, I., Kerscher, T., Rüschendorf, F., Esparza-Gordillo, J., Worm, M.,
Gruber, C., Mayr, G., Albrecht, M., Rohde, K., Schulz, H., Wahn, U., Hubner, N., Lee,
Y.A., 2007. Variants in a novel epidermal collagen gene COL29A1 are associated
with atopic dermatitis. PLoS Biol. 5, e242.
Squarzoni, S., Sabatelli, P., Bergamin, N., Guicheney, P., Demir, E., Merlini, L., Lattanzi, G.,
Ognibene, A., Capanni, C., Mattioli, E., Columbaro, M., Bonaldo, P., Maraldi, N.M.,
2006. Ultrastructural defects of collagen VI filaments in an Ullrich syndrome patient with loss of the alpha3 VI N10-N7 domains. J. Cell. Physiol. 206, 160–166.
Telfer, W.R., Busta, A.S., Bonnemann, C.G., Feldman, E.L., Dowling, J.J., 2010. Zebrafish
models of collagen VI-related myopathies. Hum. Mol. Genet. 19, 2433–2444.
Todorova, L., Bjermer, L., Westergren-Thorsson, G., Miller-Larsson, A., 2011. TGFβ-induced matrix production by bronchial fibroblasts in asthma: Budesonide and formoterol effects. Respir. Med. 105, 1296–1307.
Vainzof, M., Zatz, M., 2003. Protein defects in neuromuscular diseases. Braz. J. Med. Biol.
Res. 36, 543–555.
Voermans, N.C., Jenniskens, G.J., Hamel, B.C., Schalkwijk, J., Guicheney, P., van Engelen,
B.G., 2007. Ehlers–Danlos syndrome due to tenascin-X deficiency: muscle weakness and contractures support overlap with collagen VI myopathies. Am. J. Med.
Genet. A 143A, 2215–2219.
196
P. Sabatelli et al. / Matrix Biology 31 (2012) 187–196
von der Mark, H., Aumailley, M., Wick, G., Fleischmajer, R., Timpl, R., 1984. Immunochemistry, genuine size and tissue localization of collagen VI. Eur. J. Biochem.
142, 493–502.
Wagener, R., Gara, S.K., Kobbe, B., Paulsson, M., Zaucke, F., 2009. The knee osteoarthritis
susceptibility locus DVWA on chromosome 3p24.3 is the 5′ part of the split
COL6A4 gene. Matrix Biol. 28, 307–310.
Wipff, P.J., Hinz, B., 2008. Integrins and the activation of latent transforming growth
factor beta1 — an intimate relationship. Eur. J. Cell Biol. 87, 601–615.
Zanotti, S., Mora, M., 2006. Proteoglycans are differentially altered in muscular dystrophies. Sci. World J. 6, 446–448.
Zanotti, S., Saredi, S., Ruggieri, A., Fabbri, M., Blasevich, F., Romaggi, S., Morandi, L.,
Mora, M., 2007. Altered extracellular matrix transcript expression and protein
modulation in primary Duchenne muscular dystrophy myotubes. Matrix Biol. 26,
615–624.
Zanotti, S., Gibertini, S., Mora, M., 2010. Altered production of extra-cellular matrix
components by muscle-derived Duchenne muscular dystrophy fibroblasts before
and after TGF-beta1 treatment. Cell Tissue Res. 339, 397–410.
Zhou, L., Porter, J.D., Cheng, G., Gong, B., Hatala, D.A., Merriam, A.P., Zhou, X., Rafael, J.A.,
Kaminski, H.J., 2006. Temporal and spatial mRNA expression patterns of TGF-beta1, 2,
3 and TbetaRI, II, III in skeletal muscles of mdx mice. Neuromuscul. Disord. 16, 32–38.
Zou, Y., Zhang, R.Z., Sabatelli, P., Chu, M.L., Bönnemann, C.G., 2008. Muscle interstitial
fibroblasts are the main source of collagen VI synthesis in skeletal muscle: implications for congenital muscular dystrophy types Ullrich and Bethlem. J. Neuropathol.
Exp. Neurol. 67, 144–154.
Zweers, M.C., Bristow, J., Steijlen, P.M., Dean, W.B., Hamel, B.C., Otero, M., Kucharekova,
M., Boezeman, J.B., Schalkwijk, J., 2003. Haploinsufficiency of TNXB is associated
with hypermobility type of Ehlers-Danlos syndrome. Am. J. Hum. Genet. 73,
214–217.